Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biofrontera Inc. - Common Stock (NQ:BFRI)

1.060 -0.045 (-4.07%)
Streaming Delayed Price Updated: 2:42 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biofrontera Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Why Is TruGolf (TRUG) Stock Up 35% Today?
TruGolf stock is rallying on Friday after shares of TRUG fell hard on Thursday with their first day of trading after a SPAC merger. 
Via InvestorPlace
Why Is Biofrontera (BFRI) Stock Down Today?
Biofrontera stock is experiencing extreme volatility on Friday morning with BFRI shares starting off up but falling shortly after that rally. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers worth keeping tabs on Friday! 
Via InvestorPlace
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023
Via ACCESSWIRE
Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera's Earnings Outlook
 
Via Benzinga
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Announces $4.5M Registered Direct
Via Investor Brand Network
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
Via ACCESSWIRE
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Earnings Outlook For Biofrontera
 
Via Benzinga
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
Via ACCESSWIRE
Biofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10
Via ACCESSWIRE
Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another busy day of trading as we go over the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
Via ACCESSWIRE
Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%
Via ACCESSWIRE
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
Via ACCESSWIRE
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)
Via ACCESSWIRE
Earnings Scheduled For August 11, 2023
Companies Reporting Before The Bell • Consolidated Water Co (NASDAQ:CWCO) is estimated to report quarterly earnings at $0.22 per share on revenue of $30.27 million. 
Via Benzinga
Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
Via ACCESSWIRE
Biofrontera Inc. Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.